In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
Navigating the CDMO proposal process
BackgroundWhen businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Cellectis and AstraZeneca in US$2.2bn deal
Latest NewsAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies.
Alfasigma SpA set to take over Galapagos programme
Latest NewsItalian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos.
Abingworth raises $356m for new CCD fund
Latest NewsRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes.
Your Portable Rapid Test Reader
ProductsThe Future of Diagnostic: Portable. Everywhere. Every time. The ESEQuant® Go offers new possibilities for home and self-testing. Take your healthcare into your own hands.
Study links TCM with effects on protein networks
Latest NewsBy mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms.
Challenges in the central lab
BackgroundClinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing itself as an emerging central and specialty lab in the U.S.
BioNtech reports Car-T/mRNA booster study results at ESMO
Latest NewsBioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
Roche acquires Telavant Holdings to win TLA1 race
Latest NewsAnalysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.
UK boosts AMR defenses with £30m PACE initiative
Latest NewsIn an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.